FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme backs FY24 adjusted EPS view $4.00-$4.20, consensus $4.14
- Halozyme announces Takeda receives approval for HYQVIA by MHLW
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
- Halozyme reports FDA approval for Opdivo co-formulated with Enhanze
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz